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ABSTRACT
CREATING AN INTERNET-BASED DATABASE
OF
BETA THALASSEMIA MUTATIONS
by Shalu Susan George

Beta thalassemia, one of the most common single-gene disorders world-wide, is
caused by some 200 mutations in the beta globin gene. The disease, in its most severe
form, can result in a chronic anemia which can only be treated with repeated blood
transfusions. In order to inform and educate students, patients, the general public, and
possibly the medical community, about this incurable but preventable disease, an
internet-based database was created containing information regarding various mutations
that result in beta thalassemia. MySQL was used to create the database back-end, while
PHP, JavaScript, and Dreamweaver were used to make the front-end.

The database

currently contains 106 mutations, drawn from 139 literature references.

The user-

friendly database also provides the entire sequence of the beta globin gene, in a clickablemap format, as well as the ability to generate filtered mutation lists.
improvements have been planned for this database.

Many future
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Chapter 1 Introduction
The thalassemias, including alpha and beta thalassemia, are the most common
monogenic diseases in humans.

Thalassemia was first recognized as a disorder by

researchers in the United States and Italy, in 1925 (Weatherall, 2004). The name of the
disease was coined by George Whipple and is derived from the Greek words meaning
"sea" and "blood" due to the mistaken notion that the disease was restricted to individuals
of Mediterranean origin (Weatherall, 2004). Over the years, however, it became apparent
that the disease was equally, if not more prevalent, in many parts of the world.

1.1 The Thalassemias
The thalassemias are disorders of hemoglobin. Hemoglobin is the major protein
found in red blood cells and is responsible for binding and carrying oxygen from the
lungs to the various body tissues. Each hemoglobin molecule is a tetramer, made up of
two alpha-like globin chains and two beta-like globin chains. Each globin chain has a
heme group attached (Weatherall, 2004). Oxygen is bound and transported through the
heme-groups.
A heme group is a prosthetic group, that is, it is a non-protein group bound to a
protein. The heme group consists of an iron atom contained in the center of a large
heterocyclic organic ring called a porphyrin (Casiday & Frey, 1998). The heme group is
bound to a histidine residue in the globin protein.

Both the heme group and the

hemoglobin protein undergo conformational changes upon the binding and unbinding of
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oxygen. These changes in shape improve the efficiency of the hemoglobin molecule,
enabling it to bind or release more oxygen (Casiday & Frey, 1998)
Abnormalities in hemoglobin, resulting from the deficiency or complete absence
of one or more of the globin chains, give rise to the thalassemias.

Patients with

thalassemia suffer from varying degrees of anemia, that is, a shortage of red blood cells
(Weatherall & Clegg, 2001).

1.2 Beta Thalassemia
One major type of thalassemia is beta thalassemia, which results from a disorder
in the production of beta globin. In the fetus, the primary beta-like globin is gammaglobin; however, soon after birth, a switch in globins takes place such that beta globin
replaces gamma-globin (Weatherall, 2004). The major adult hemoglobin, called HbA,
thus contains alpha globin and beta globin. The symptoms of beta thalassemia become
apparent in a patient, only a few months following birth, when the switch to adult
hemoglobin occurs (Weatherall, 2004).
Beta thalassemia poses the greatest burden on health care, compared to the other
thalassemias, where the most severe forms of the disease often lead to death in-utero.
Beta thalassemia symptoms develop within the first two years of birth and without
treatment a patient, with the most severe form of the disease, would die by 20 years of
age. The clinical description of beta thalassemia was first published in the US by two
Detroit based physicians - Thomas B. Cooley and Pearl Lee.

As a result, beta

thalassemia is often also referred to as Cooley's anemia (Weatherall, 2004).
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1.3 Genetic Cause of Beta Thalassemia
Beta thalassemia is caused by mutations in the beta globin gene. The gene is part
of the beta globin locus, located on chromosome 11, in humans (Nienhuis, Anagnou, &
Ley, 1984). Mutations in the gene result in either a deficiency of beta globin, referred to
as beta+ thalassemia, or a complete lack of beta globin, referred to as betaO thalassemia
(Weatherall, 2004). The disease is an autosomal recessive disease, meaning that
individuals that have the most severe form of the disorder carry two mutations - one in
their paternal gene and one in their maternal gene. The disorder varies in severity.
Individuals with beta thalassemia minor carry a mutation in only one of their two genes
and have little to no symptoms. Those with beta thalassemia intermedia carry a mutation
in either one or both of their genes and have moderate symptoms. Patients with beta
thalassemia major have a mutation in both their genes and are the worst affected,
requiring blood transfusions every 8-12 weeks or more frequently (Weatherall, 2004).
Some 200 different mutations give rise to beta thalassemia. Most thalassemia major
patients are compound heterozygotes and carry a different mutation in each gene
(Weatherall, 2004).

1.4 The Link between Beta Thalassemia and Malaria
J. B. S. Haldane, in 1945, was the first one to suggest a connection between the
high frequencies of thalassemia, seen in some parts of the world, and the prevalence of
malaria in these regions. He believed that individuals that were heterozygous for globin
mutations were somehow protected against a deadly case of malaria. This idea came to
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be known as the Haldane hypothesis. The mechanism of this protection, in the case of
thalassemia, is not clear (Kwiatkowski, 2005). Protection has been attributed to the
inability of the parasite to invade or grow in the distorted red blood cells or the inability
of the parasite to complete its lifecycle due to premature destruction of the mutant red
blood cells (Ayi, Turrini, Piga, & Arese, 2004). Malaria, a deadly killer responsible for
millions of deaths annually, has acted as one of the strongest evolutionary forces for the
selection and maintenance of protective globin mutations in human populations
(Kwiatkowski, 2005).

1.5 Distribution of Beta Thalassemia
Beta thalassemia has been prevalent in many parts of the Old World, especially in
the so called malaria belt. The disease is prevalent, not only in the regions surrounding
the Mediterranean, but also in Africa, the Middle East, the Indian subcontinent, Southeast Asia, and Southern China (Vichinsky, MacKlin, Waye, Lorey, & Olivieri, 2005;
Weatherall, 2004). A few mutations dominate in each region while the rest of the
mutations are not so commonly seen (Weatherall, 2004).
Beta thalassemia was brought to the New World by immigrants from the
Mediterranean region, Africa, and, more recently, Asia (Vichinsky et al., 2005).

1.6 Phenotype of Beta Thalassemia
Beta thalassemia affects multiple organs but the primary phenotype of the
disorder is hemolytic anemia (Cunningham, Macklin, Neufeld, & Cohen, 2004). Each
red blood cell contains millions of hemoglobin molecules. Beta thalassemia patients, due
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to their deficiency of beta globin, have abnormal hemoglobin, and, as a result, their red
blood cells are microcytic, that is, they are smaller than normal and they have lower
hemoglobin content. These mutated red blood cells are recognized as defective by the
spleen, and are destroyed prematurely (Cunningham et al., 2004). The premature
destruction of red blood cells leads to a severe case of anemia.
The spleen, in the process of destroying large numbers of red blood cells,
becomes hyperactive and enlarged, a condition referred to as splenomegaly (Cunningham
et al., 2004; Weatherall & Clegg, 1996). The iron, from the destroyed red blood cells, is
normally stored in the liver and spleen, so that it can be used later on to make new cells.
However, in patients, the rapid destruction of high numbers of red blood cells leads to an
iron overload in the liver and spleen, as well as in many other organs, leading to organ
failure. Patients often suffer from hepatitis or liver carcinoma. Iron overload in the
ovaries, testes, and hypothalamus leads to infertility, in the pancreas it leads to diabetes,
in the gall bladder it leads to gall stones, while in the heart it leads to irregular heart-beat
and heart failure (Cunningham et al., 2004).
The hyperactive spleen not only destroys red blood cells, but also some white
blood cells, which in turn causes immunosuppression (Cunningham et al., 2004). The
bone marrow, which is the site of red blood cell production, also expands, to keep up
with the large requirement of new cells, needed to replace the destroyed ones. This
expansion of the bone marrow causes the bones to become fragile and results in an
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enlargement of the skull and facial deformities in untreated children (Cunningham et al.,
2004; Weatherall & Clegg, 1996).

1.7 Treatment for Beta Thalassemia
There are no cures for beta thalassemia and the disease can only be managed
through frequent blood transfusions, iron chelation therapy, and splenectomy (surgical
removal) in case of an enlarged spleen (Cunningham et al., 2004). Chronic cases are
treated with monthly transfusions of "washed, filtered, or frozen red cells" (MarengoRowe, 2007). Most of the mortality associated with beta thalassemia results from ironoverload and hence all long-term transfusion programs are accompanied by treatment
with an iron-chelating agent.

The most widely used iron-chelator is deferoxamine

(Cunningham et al., 2004; Marengo-Rowe, 2007). As it is poorly absorbed from the
gastrointestinal tract, it has to be administered intravenously or subcutaneously, through a
metering pump, 4-5 times a week, and for a period of 8 hrs (Marengo-Rowe, 2007).
Alternative therapies that are being considered include reactivation of fetal
hemoglobin, bone marrow transplantation, and somatic gene therapy (Marengo-Rowe,
2007). The levels of fetal hemoglobin (HbF) generally drop soon after birth. However, it
has been found that continuing to maintain high levels, using various therapeutic agents
like erythropoietin, hydroxyurea, and cytarabine, can decrease the frequency of
transfusions. HbF reactivation therapy only works for some patients (Marengo-Rowe,
2007).
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Bone marrow transplantations from a human leukocyte antigen (HLA) matched
donor have been performed for about a thousand patients in the US. This therapy works
only for children and has many associated risks (Marengo-Rowe, 2007; Weatherall,
2004). Gene therapy to treat beta thalassemia has not been very successful as it is difficult
to achieve the fine-tuned balance between alpha and globin chain production seen in
normal cells (Marengo-Rowe, 2007).

1.8 Diagnosis and Prevention of Beta Thalassemia
As beta thalassemia requires life-long management, it puts a great deal of pressure
on patients and the public health system. Prevention, through carrier screening and
prenatal diagnosis, thus becomes vitally important. Primary screening involves various
hematological tests, such as measurements of mean corpuscular volume (MCV), which is
a measure of the size of a red blood cell, and mean corpuscular hemoglobin (MCH),
which is a measure of the hemoglobin content of a red blood cell (Old, 2003). High
Pressure Liquid Chromatography (HPLC) is used to look at the hemoglobin profile
(Bhardwaj, Zhang, Lorey, McCabe, & McCabe, 2005; Lorey, 2000; Old, 2003). Patients
with beta thalassemia have elevated levels of HbA2 (the secondary adult hemoglobin)
and HbF (fetal hemoglobin) (Old, 2003).
If a patient is found to be a carrier, further testing is carried out to identify the
mutation. Tests such as reverse dot blot or various PCR based methods are used to test
for specific mutations (Bhardwaj et al., 2005; Old, 2003). 90% of the mutations can
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usually be identified in this manner. For the remaining 10%, rare mutations, the entire
beta globin gene is sequenced (Old, 2003).
When both parents are carriers, they have a 25% probability of having a
thalassemia major child.

In such cases, prenatal diagnosis is highly recommended.

Amniocentesis or chorionic villus sampling (CVS) is commonly used for this purpose
(Marengo-Rowe, 2007; Old, 2003). Amniocentesis involves using a needle to withdraw
amniotic fluid, which contains the cells of the fetus. These cells can then be tested to
determine the fetus's genotype. Alternatively, CVS can be carried out earlier in the
pregnancy. CVS involves inserting a catheter through the cervix and withdrawing a piece
of tissue from the outer layer of the embryo sac. This tissue has the same genotype as the
fetus.

If the fetus is found to have beta thalassemia major, the parents can opt to

terminate the pregnancy.
In order to avoid the trauma of pregnancy termination, parents can also opt for an
expensive procedure called pre-implantation diagnosis. In this procedure a number of
embryos are prepared in-vitro from which a healthy embryo is then chosen and implanted
(Marengo-Rowe, 2007).

1.9 Purpose of the Database
The beta thalassemia database, created as part of this project, will help increase
awareness about the disease amongst the general public. The database could also be used
as a teaching and learning tool in academic settings as well as in hospitals to educate
patients and those in the allied medical professions.
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The disease database could be utilized as an awareness tool as it contains
information about the causative mutations and the affected populations. In the future, the
database will include disease related information and links, as well as the basics of
genetics and hematology. Thus, users will not only learn about the disease, but also will
become aware of whether they belong to a high-risk community.
In the United States (US), thalassemia was previously considered as a disease
only afflicting Mediterranean immigrants. Since the 1980's, however, the US has seen a

sharp increase in immigration from various Southeast Asian countries where beta
thalassemia is found at a higher frequency (Vichinsky et al., 2005; Lorey, 2000). As a
result, beta thalassemia is rapidly emerging as "a new minority disease" in this country
(Vichinsky et al., 2005). As beta thalassemia has no cure, management of the disease
involves providing monthly blood transfusions to an ever growing number of patients;
this in turn increases the pressure on blood banks and burdens the health care system.
Under these circumstances, spreading awareness about the disease and promoting
prevention, through carrier screening and prenatal diagnosis programs, becomes
imperative. The database will contribute towards this effort in the US where knowledge
of the disease has been found to be poor, even in highly susceptible communities
(Armeli, Robbins, & Eunpu, 2005).
The only database for the hemoglobinopathies currently available to medical
professionals, patients, researchers, and students alike, is called HbVar (described in
detail in Chapter 2 Section 2.1), based at Penn State University (Patrinos, Giardine,
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Riemer, Miller, & Chui, 2004). This database includes all globin mutations rather than
just beta thalassemia mutations. The database is not very user-friendly, especially for
non-professionals, and assumes considerable background knowledge of the disease and
its genetics. Also, no web site or database on the internet, including HbVar, currently
contains the entire sequence of the beta globin gene. The beta thalassemia database,
created as part of this project, overcomes these deficiencies. The database not only
provides the entire beta globin gene sequence, in an easy-to-follow format, but also is
intuitive to use and hence can be easily utilized as a learning tool.
The database could also be employed as a teaching aid in courses of genetics,
bioinformatics, and hematology. The database provides many tools to allow students to
learn more about beta thalassemia, its distribution, and the mutations that give rise to it.
The references provided for each mutation, with links to the article abstracts, give users
an opportunity to further explore the disease and its many interesting variations. Since
the beta globin gene is a fairly small gene, and is not alternatively spliced, it is ideal for
studying genetic concepts like transcription, splicing, and translation. The size of the
gene also makes it easier to understand gene structure. Since beta thalassemia involves
some 200 mutations, including insertions, deletions, and substitutions, the database could
educate students about the different types of mutations and their consequences. Students
also have the option of learning the effect of a base insertion, deletion, or substitution by
manipulating the beta globin sequence provided by the web site.
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Finally, the database could be utilized in a hospital setting, to educate nurses and
those in the allied medical fields. It could also be used by genetics counselors to help
patients and their families better understand the disease.
The following chapters describe the process involved in the creation of the
database as well as the database content.

Chapter 2 deals with the design and

implementation of the database back-end. Chapter 3 provides the details of the various
web pages that make up the database front-end. Chapter 4 gives an overview of the
records in the database. Finally, some ideas for future improvements of the database are
presented in Chapter 5.
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Chapter 2 Creation of the Database Back-end
The back-end is that portion of software that is not directly accessible to an enduser. It generally includes the Database Management System (DBMS) which is used to
organize and store data.
The creation of the database back-end involved identifying the data sources,
collecting mutation-related data from the sources, installing the software needed for
database creation, creating and implementing the database design, and, finally, populating
the created database with the gathered data.

2.1 Data Sources
The mutations for the database were gathered from three sources (a) HbVar, an
online database of hemoglobin variants and thalassemia mutations (Wajcman, Patrinos, &
Anagnou, 2008), (b) The Thalassaemia Syndromes, the book by Weatherall and Clegg
(2001), and (c) PubMed, an online database of citations and abstracts of biomedical
research articles ("NCBI: PubMed," 2008).
The HbVar Database. The HbVar database is a "publicly available database" based at
Perm State University, PA, USA (Patrinos et al., 2004) and was created through an
association between Perm State University, INSERM Creteil, France and Boston
University Medical Center, MA, USA (Wajcman et al., 2008). The initial data for HbVar
was drawn from the books A Syllabus of Human Hemoglobin Variants (Huisman, Carver,
& Efremov, 1998) and A Syllabus of Thalassemia Mutations (Huisman, Carver, & Baysal,

12

1997). The database is maintained and updated with new mutations by three curators Dr. Henri Wajcman, Dr. George Patrinos, and Dr. Nick Anagnou (2008).
The database claims to provide the most current information on different types of
mutations that result in thalassemia (Wajcman et al., 2008). The information provided
for a mutation includes sequence changes, the hematological and pathological effects of
the mutation, the population-wise distribution of the mutation, and list of references
(Patrinos et al., 2004). The database is primarily aimed at researchers and those in the
medical community.
The HbVar database served as one of the sources for mutations and their
references.

The mutation description was taken from HbVar and each of the cited

references was referred to for further information about the mutation. The information
obtained from the references was then cross-checked with what had been recorded by
HbVar.
"The thalassaemia syndromes" by Weatherall and Clegg (2001).

Sir David J.

Weatherall, the primary author of the book The thalassaemia syndromes, is a
distinguished

and

multi-award-winning

geneticist

who

has

made

outstanding

contributions to the field of thalassemia research (Kan, 2004). He published his first
paper on thalassemia as early as 1960 and spent nearly 40 years pioneering countless
discoveries and authoring as many as 14 books and 600 papers on the subject (Kan,

2004). His above mentioned book, which is currently in its 4 edition, is unarguably
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regarded as "the Bible" of thalassemia and is a "must read" for anyone in this line of
research (Kan, 2004).
Dr. Weatherall's book was used as an added data source. Additional mutations,
not included in the HbVar database, were obtained from the book. For mutations
common to both the book and HbVar, extra references, cited in the book but not in
HbVar, were noted.
The PubMed Database. PubMed, a database maintained by the National Library of
Medicine, is a collection of over 16 million abstracts and citations of articles from almost
every well known biomedical journal ("NCBI: PubMed," 2008). The article citations also
include a link to the full-text article.
The PubMed database was used to access the reference articles for each mutation.
In addition, the database was used to search for articles reporting any newly discovered
mutations. A few new mutations were found in articles published in late 2007 and early
2008.
Some mutation entries in the HbVar database are based on personal
communications, from researchers, received by the curators of HbVar. Some of these
researchers, at a later date, publish a journal article based on the same findings.
However, the HbVar entries are not updated with the journal citations. Hence, in cases
where citations were absent, the PubMed database was searched for such a possible
article by the researcher.
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2.2 Data Collection
The gathered information for each mutation was initially recorded in a paperbased form. The mutation description and disease type (betaO, beta+) were noted from
the data source. The mutation type (substitution, insertion or deletion) was derived from
the mutation description. The starting position of the mutation, the mutation length, and
the mutation location were deduced from the sequence of the beta globin gene. The
effect of the mutation was either obtained from the references or was inferred on the basis
of basic genetic principles.

The disease severity (thalassemia major, intermedia or

minor), the disease distribution (by nationality and ethnicity), and frequency of
occurrence (common, rare, novel) were drawn from the references.

Additional

noteworthy facts, found in the references, were recorded as comments. The reference
citations and PubMed identification numbers (PMIDs) were taken from the PubMed
database.

2.3 Software Used for Database Back-end
Virtual Machine - Vmware. In order to create the back-end, a virtual machine was first
setup using VMware.

VMware is software that aids in the creation of an abstract

machine within a machine ("VMware: Virtualization Basics," 2008). It creates the effect
of having two separate, independent computers within a physical computer. The virtual
machine is referred to as the guest system, while the physical computer is referred to as
the host system ("VMware: Virtualization Basics," 2008).
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A VMware virtual machine provides many advantages.

It allows the use of

multiple operating systems on the same computer ("VMware: Virtualization Basics,"
2008). It enables users to switch between operating systems without actually re-booting
the computer. The virtual machine is also portable ("VMware: Virtualization Basics,"
2008). All the contents of the VMware virtual machine are stored in a single folder and
hence can easily be moved or copied onto a different computer. The virtual machine can,
in addition, acquire its own IP address and use it to communicate with the host system
over a network ("VMware: Virtualization Basics," 2008).
Since it was decided to create the database in a Linux operating system
environment, a virtual machine was required to enable easy switching between the
Windows XP and Linux operating systems.
Operating System - CentOS 5.

CentOS is a "Community ENTerprise Operating

System," which means that it is a freely available, non-commercial software that is
maintained and updated by a community of open source contributors ("CentOS: Home
page"). CentOS is based on Red Hat Enterprise Linux which is a commercial product.
The advantages of CentOS are that it is a robust and reliable operating system. It
also comes with the latest versions of various server and application software, including
MySQL 5.0.
CentOS was chosen as the operating system because it was freely available and
included the latest version of the database management system MySQL. CentOS also
provided a stable development environment.
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Database Management System - MySQL 5.0. MySQL, which stands for Structured
Query Language, is a very popular, openly available, DBMS. MySQL is popularly used
for web applications. It is used by many well known web sites such as YouTube, Flickr,
Friendster, Wikipedia, Adobe, and Nokia. It can store large amounts of data, is flexible,
and is fast at both storing and retrieving data ("Top reasons to use MySQL").

2.4 Designing the Database
Database designing involves firstly, identifying the data to be stored in the
database and secondly, choosing appropriate structures to represent and store the data.
Database designing is the first step in creating a database and it is done before the actual
database is created and populated with data.
The description of a database is called the database schema. The schema is
defined during the designing phase and is not expected to change frequently. Different
types of database schemas, based on different sets of rules, can be made. For this
database, an Entity-Relationship (ER) schema was created (shown in Figure 2.1).
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USER COMM
C^Entry_dtime"*])

^Usr_name

Figure 2.1. The Entity-Relationship database schema.
The ER schema is a popular high-level conceptual data model (Elmasri &
Navathe, 2007). It views the database in terms of entities and relationships. Rectangular
boxes are used to depict the entities. An entity is any real world object or a concept.
Five entities were defined - MUTATION, DISTRIBUTION, REFRENCES, CURATOR,
and USER_COMM (user comments).
Double rectangular boxes stand for weak entities. A weak entity is one that
cannot exist by itself and depends on another entity for its existence.
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In this case

DISTRIBUTION is a weak entity that depends on the entity MUTATION or, in other
words, a distribution does not make sense till it is tied to a mutation.
Ovals are used to represent the attributes of an entity. An attribute is a property
that describes an entity. The attributes that are primary keys are underlined by a solid
line (e.g., MutID, RefID). A primary key is an attribute that can be used to uniquely
identify each instance of an entity. Weak entities do not have complete primary keys;
instead they have partial keys.

Partial keys are underlined by a broken line (e.g.,

Nationality, Ethnicity). The primary key of a weak entity is constructed by combining its
partial key with the primary key of the related strong entity (also called the owner entity).
In this case Nationality and Ethnicity need to be combined with MutID in order to
construct a primary key for DISTRIBUTION. An attribute that can have multiple values
is surrounded by a double oval.
Diamonds are used to represent the relationships between the entities.

A

relationship is the association between two or more entities. Double diamonds are used
to depict the relationships of weak entities.
Lines connecting the diamonds to the boxes stand for the participation of an entity
in a relationship.

Partial participation is represented by a single line.

A partial

participation, for instance, is seen between the entity MUTATION and the relationship
HAS, since a mutation may or may not have a user comment. Total participation, on the
other hand, is represented by double lines. Total participation is seen between the entity
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USER_COMM and the relationship HAS, as a user comment must have a mutation
associated with it.
Furthermore, the type of relationship is given alongside the lines. A relationship
could be one-to-one (1:1), one-to-many (1:N) or many-to-many (M:N). The entities
MUTATION and REFRENCES have a many-to-many relationship because one mutation
can have multiple references and, at the same time, one reference can have multiple
mutations associated with it.

On the other hand, entities MUTATION and

DISTRIBUTION have a one-to-many relationship because one mutation can have
multiple populations associated with it.
An ER schema is best suited for end users and helps them perceive data (Elmasri
& Navathe, 2007). However, a schema that can be both understood by end users and, at
the same time, can easily be implemented on a computer is the Relational schema. The
ER schema can easily be mapped to a Relational schema.
2.5 Implementing

the Database

Design

A Relational schema was created to enable the implementation of the database
design. An ER-to-Relational Mapping Algorithm from Elamsri and Navathe (2007, pp.
224-30) was used. The Relational schema is shown in Figure 2.2.
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Figure 2.2. The Relational database schema.
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The mapping steps used to create the schema are described below:
Step 1: Mapping of Regular Entity Types. For each regular (strong) entity type in the
ER schema, a relation was created that included all the attributes of the entity (a relation
is synonymous to a table of the database). A primary key was also chosen for each
relation.

Thus, the relations

MUTATION,

REFRENCES,

CURATOR,

and

USER_COMM were created. The primary key for each of these relations is depicted in
bold in Figure 2.3. The primary key for MUTATION is MutID (mutation ID), for
REFRENCES is RefID (reference ID), for CURATOR is Updn_dtime (updation date and
time), and for USER_COMM is Entrydtime (entry date and time).
Step 2: Mapping of Weak Entity Types. For each weak entity type in the ER schema, a
relation was created that included all the attributes of the entity. In addition, the primary
key of the owner entity was included as a foreign key attribute. Thus, the relation
DISTRIBUTION was created and MutID, from the relation MUTATION, was included
as a foreign key. The foreign key, MutID, is depicted as underlined in Figure 2.3. The
source of the foreign key is indicated with an arrow.

The primary key of

DISTRIBUTION is a combination of the partial keys Nationality, Ethnicity, and the
primary key of its owner MutID.
Step 3: Mapping of Binary 1:1 Relationship Types. For each 1:1 relationship type in
the ER schema, a corresponding relationship was established between the relations in the
Relational schema. The primary key of one participant in a 1:1 relationship was included
as a foreign key of the other participant. Thus, to map the 1:1 relationship between the
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entities MUTATION and CURATOR, the primary key of the MUTATION relation was
included as a foreign key in the CURATOR relation.

The foreign key, MutID, is

depicted as underlined in Figure 2.3. The source of the foreign key is indicated with an
arrow.
Step 4: Mapping of Binary 1:N Relationship Types. For each 1:N relationship type in
the ER schema, a corresponding relationship was established between the relations in the
Relational schema. The primary key of the participant on the l-side of the relationship
was included as a foreign key of the participant on the N-side. Thus, to map the 1 :N
relationship between the entities MUTATION and USER_COMM, the primary key of
the MUTATION relation was included as a foreign key in the USER_COMM relation.
The foreign key, MutID, is depicted as underlined in Figure 2.3. The source of the
foreign key is indicated with an arrow.

The 1:N relationship between the entities

MUTATION and DISTRIBUTION was mapped in a similar manner.
Step 5: Mapping of Binary M:N Relationship Types. For each M:N relationship type
in the ER schema, a new relation was created to represent the relationship between the
participating entities. The primary keys of the participating relations were included as
attributes in the new relation. Thus, to map the M:N relationship between the entities
MUTATION and REFRENCES, a new relation REFERSTO was created. RefID from
REFRENCES and MutID from MUTATION were included as attributes of
REFERS_TO. The primary key of REFERS_TO is a combination of the foreign keys
MutID and RefID. The primary-cum-foreign keys, MutID and RefID, are depicted as
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bold and underlined in Figure 2.3. The source of the foreign keys is indicated with
arrows.
Step 6: Mapping of Multi-valued Attributes. For each multi-valued attribute in the ER
schema, a new relation was created. This relation included its own attribute plus the
primary key of the entity of which the relation is an attribute. Thus, for the multi-valued
attribute Dissev of MUTATION, a new relation DISEASESEV was created that
contained the attribute Dissev and the primary key, MutID, of MUTATION.

The

primary key of DISEASESEV is a combination of Dis_sev and the foreign key MutID.
The primary key is shown in bold and the foreign key is underlined in Figure 2.3. The
source of the foreign key is indicated with arrows. The multi-valued attribute Dis_type
was mapped in a similar mariner.
Step 7: Mapping of N-ary Relationship Types. As there were no n-ary relationship
types in the ER schema, this step was omitted.
2.6 Population

of the

Database

Manual Population. The first 70 records in the database were entered using batch files.
A batch file is a text file containing a series of commands that can be executed in a
sequence, one after the other, just as if they were typed in manually (Weddell, 2003).
MySQL commands, to insert records into the database, were written into a text file and
the text file was then executed. Each batch file inserted 10 records into the database.
The database entries were verified against the paper-based records.
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This method of data entry was used at the start because the front-end data entry
form had not as yet been constructed. The use of batch files was also advantageous as it
enabled the modification and fine-tuning of the database schema. Following changes to
the schema, batch files allowed easy deletion and reentry of records.
Automated Population. Once the mutation data entry form was constructed, as part of
the front-end, mutations were entered one at a time using the browser-based form.
Thirty-six mutations were entered in this manner. This method of data entry was also
helpful in testing and de-bugging the underlying front-end code. The data entry form will
be discussed in greater detail in Chapter 3.
The next chapter describes the web pages that make up the front-end of the
database, the software that was used to generate the pages, as well as the three tier
architecture that was used to establish communication between the front-end and the
database.
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Chapter 3 Creation of the Database Front-end
The front-end is that portion of software or a web site that is directly accessible to
the end-user and is used to interact with or access other inaccessible parts of the software
or web site. In this case, the database forms the back-end, while a web site forms the
front-end. The web site, through web pages, allows the end-user to view the contents of
the database, to enter data into the database and to query (request specific data from) the
database.

What access and how much access an end-user has to the database are

determined by the web page designer.
The creation of the database front-end involved installing the needed software,
establishing a connection between the database and the front-end, and writing the scripts
to generate the required web pages such as the mutation map, the mutation details page,
the new mutation input form, and the mutation list query page.

3.1 Software Used for Front-end
XAMPP for Windows. The name XAMPP is an acronym for X (the X stands for the
many operating systems it supports) Apache MySQL PHP Perl ("XAMPP," 2008).
XAMPP is an installer that helps in the easy installation of Apache, PHP, and MySQL on
a computer (McFarland, 2007).
XAMPP was used as it is freely available.
download and install (Seidler, 2007).

It is also very easy and fast to

It provides an Apache HTTP server and an

interpreter for the PHP scripting language (McFarland, 2007), both of which were
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required to generate dynamic pages. XAMPP also enables testing of front-end scripts
without actually connecting to the internet (McFarland, 2007).
Web Server - Apache 2.2. A web server is a program that accepts HTTP (hyper text
transfer protocol) requests for web pages from a client (Brookshear, 2007). The client
sending the HTTP request is a web-browser such as Internet Explorer, Mozilla Firefox,
Safari or Opera. The request could be sent when, for instance, a user types a web address
(URL) into the address bar of the browser or when a hyperlink is clicked on or a
"Submit" button is pressed. The server responds with a web page (HTML document)
which is then displayed by the browser (Brookshear, 2007).
The content that is sent by the server is static if it comes from an existing file,
such as a text file or HTML page (McFarland, 2007). However, the content is said to be
dynamic if it comes from another program. Data that is pulled from a database by a
program or script is considered dynamic (McFarland, 2007).
Apache was used as it is one of the most popular HTTP servers on the World
Wide Web (Pfaffenberger, 2003), is free, provides support for the server-side scripting
language of choice PHP, and can be locally installed to test code during development.
Server-side Scripting - PHP 5.1. Server-side scripting is used to generate dynamic
HTML pages. A request sent to the web server, by the browser, is fulfilled by executing
a script at the web server (Brookshear, 2007). Server-side scripting enables the user to
access data stored in the database. It can also be used to validate data prior to its input
into the database.
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PHP is a widely used server-side scripting language (McFarland, 2007). PHP is a
recursive acronym for PHP Hypertext Preprocessor (Pfaffenberger, 2003). PHP scripts
can easily be embedded into any HTML document by simply surrounding the code with
the delimiters <? and ?>.
PHP was used because it is freely available, is easy to learn, and works well with
the Apache web server and the MySQL database management system.
Web Development Tool - Dreamweaver CS3.
development tool.

Adobe Dreamweaver is a web

It is one of the most popular What-You-See-Is-What-You-Get

(WYSIWG) editors (McFarland, 2007). A WYSIWG editor is especially helpful for
those who have very little familiarity with web-development technologies. Dreamweaver
automatically generates the HTML code required to create a web page. However, for
those with some familiarity, it also provides a "code view" where the developer can
access and modify the automatically generated code.
Dreamweaver is suitable for generating dynamic web pages as, in addition to
automatically generating HTML code, it can generate PHP and JavaScript (used for
client-side scripting, explained in greater detail further in this section). It also provides
support for Cascading Style Sheets (CSS), which is a language that allows a developer to
specify how a web page will be presented; it allows the definition of style elements like
color, font-size, font-style, and layout and thus helps in the separation of a document's

content, given as HTML, from a document's style (Pfaffenberger, 2003).
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The new version of Dreamweaver includes a Spry framework for Ajax, developed
by Adobe. The Spry framework helps in the development of applications that use Ajax
(McFarland, 2007). Ajax, an acronym for Asynchronous JavaScript and XML, is a
collection of technologies that help in the creation of interactive web pages (Eichorn,
2006). Dreamweaver's Spry framework allows the developer to create dynamic pages on
the client-side; it allows the inclusion of animation effects, stylized menus and tabbed
panels, and form validation.
Client-side Scripting - JavaScript

Client-side scripting refers to programs that are

executed by the web browser as opposed to the web server. It allows the creation of
dynamic HTML pages where the content of the page doesn't remain fixed but changes
depending on the web site user's input (Brookshear, 2007).
JavaScript is one of the languages used to write client-side scripts. The code can
either be embedded in an HTML document or it can be included from a separate file.
JavaScript can be used to open popup windows with messages, to disable or enable the
elements in an input form based on user input, to validate form input, and to detect user
actions like clicking a mouse button or moving the cursor over a link or image. As
JavaScript is run by the browser, it can respond faster to user actions and hence can give
the web page an interactive feel (McFarland, 2007). However, JavaScript will only work
if the user's browser supports this scripting language and has it enabled.
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3.2 Establishing a Connection between the Database and the Front-end
In order to establish a connection between the database and the front-end, a
private network was set up between the host machine and the guest virtual machine (both
set up on the same computer). Dreamweaver was used to help connect to the database.

Host Machine

Virtual Machine

Windows XP

Linux

m

i

MySQL
DB

JavaScript

Figure 3.1. Three-tier architecture. The web browser forms the first tier, the
application server forms the second tier, while the database server forms the third
tier.
As described in Chapter 2, for development and testing purposes, the MySQL
database was located on the virtual machine, while the Apache web server and PHP were
located on the host machine. The guest operating system was Linux, while the host
operating system was Windows XP. Mozilla Firefox and Internet Explorer were used for
testing code. The PHP script is executed by the Apache web server, while JavaScript is
executed by the web browser being used. The three-tier setup can be seen in Figure 3.1.
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3.3 The Mutation Map
Obtaining the Sequence of the Beta Globin Gene. The sequence for the beta globin
gene was obtained from the book by Weatherall and Clegg (2001). The BLAST (Basic
Local Alignment and Search Tool) program, provided online by NCBI (National Center
for Biotechnology Information), allows comparison of sequences, to check for sequence
similarity.

Nucleotide blast, also called blastn, was used to compare the sequence

obtained from Weatherall and Clegg with all the human genomic sequences in the NCBI
database.

The sequence provided by the book and that stored by the NCBI database

were found to be completely identical.
Design of the Mutation Map. The idea of a mutation map is credited to Dr. Sami Khuri,
Professor (and thesis committee member for this project), Department of Computer
Science, San Jose State University. The original mutation map was designed by Dr.
Khuri and Keith Callenberg (2007), an undergraduate Computer Science major at San
Jose State University.
The mutation map created for this project is shown in Figure 3.2. It extends from
nucleotide -120 to +1706 of the beta globin gene. Nucleotides -120 to -1 are shown in
lower case and represent the promoter of the gene. The important regulatory elements in
the promoter, such as the two CACCC boxes, the CCAAT box, and the TATA box, are
depicted in red.

These regulatory elements are required for the optimal binding of

transcription factors and the efficient initiation of transcription (Basran, Reiss, & Luo,
2008).
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The transcribed portion of the beta globin gene is 1606 bases long and is shown in
upper case letters. The gene has three exons and two introns.

Nucleotides +1 to +50,

shown in black, represent the 5'UTR (untranslated region), which forms part of exon 1.
Nucleotide regions shown in blue represent the open reading frame of the gene. The
three nucleotides forming each codon are grouped together. The open reading frame
begins at the start codon (ATG) at position +51, in exon 1, and ends at the stop codon
(TAA) at position +1472, in exon 3. The two introns, also called intervening sequences
(IVS), are shown in black. Nucleotides +1475 to +1606, shown in black, represent the
3'UTR (untranslated region), which forms part of exon 3. The 3'UTR contains the
polyadenylation signal sequence (AATAAA), depicted in red, that signals the 3'cleavage
of the primary mRNA transcript. The 3'flanking region of the gene, extending from
nucleotide +1607 to +1706, is shown in lower case. The overall structure of the beta
globin gene can be seen in Figure 3.3.
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Figure 3.2. The mutation map (split into two columns).
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Figure 3.3 The structure of the beta globin gene. (UTR-Untranslated region)
As the cursor is moved over different bases, a hand tooltip pops up to give more
information about the related map position. The tooltip can be seen in Figure 3.4. The
tooltip includes information such as the position of the base, relative to the start point of
transcription, and the structural location of the base. If the base is part of a codon, the
codon number and the amino acid encoded by the codon are included in the tooltip. If the
base is part of an intron, the position of the base, relative to the 5' exon-intron junction, is
given.
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Figure 3.4. A customized tooltip. On the map page the tooltip provides detailed
information about every map position.
Base positions that have one or more mutations associated with them are
underlined. These underlined bases are hyperlinks that can be clicked on to open a
mutation details page (described in Section 3.4).
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The details page contains the

information about the associated mutations.

Base positions that have no attached

mutations are not underlined. Clicking on such bases produces a popup box that informs
the user that the position has no mutations recorded.
When mutations, related to a new position, are added to the database, the
corresponding base position is automatically underlined in the mutation map when the
web page reloads.
Underlying Code for the Mutation Map.

The background code that generates the

mutation map contains a series of anchor tags, each of which references the file that
contains the code for generating the mutation details page. The map position of each
base is passed to the program file so that only mutation details related to that particular
map position will be displayed.
A combination of PHP and JavaScript were used to produce both the automated
underlining of links and the popup box, generated for map positions that have no
associated records. The code has been included in Appendix A. The pseudocode is
given below:
establish a connection with the database
declare an array
for each map position
determine if there are corresponding mutations (records) in the database
if records are found
assign the map position to the array
else
if map position is clicked on
show a popup box with "no records" message
endif
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endif
endfor

if page loads
for each map position in the array
underline the corresponding map position
endfor
endif

3.4 The Mutation Details Page
Design of the Mutation Details Page.

The mutation details page contains all the

information pertaining to the mutations that were found associated with a particular map
position. A sample page, for the +140 map position, is shown in Figure 3.5. Currently,
in the database, map positions have between 0-3 mutations associated with them.
The titles of the references (seen underlined in Figure 3.5) are hyperlinks.
Clicking on the title opens up the PubMed page with the abstract for the related journal
article. Hovering over the hyperlink shows a tooltip with the PubMed identification
number (PMID) of the article.
Underlying Code for the Mutation Details Page. Primarily PHP and HTML were used.
The high-level code is given below:
establish a connection with the database
select all records from all tables where mutation position = map position passed by
hyperlink (on clicking)
if records are not found
display a message saying no records found
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else
for each record found
appropriately format and display the record
endfor
endif

Mutation Data
,
Mutation ID:

__
80

1 Mutation Description:
I
I Mutation Tvpe:

Codon 29(GGC->GGT)
Substitution - Transition. Silent

Starting Position of
Mutation:

140

Mutation Length:

1

Mutation Location:

Exon 1 - Codon 29

Mutation Affects:

mRNA processing - Creates cryptic splice site in exon

I Thalassemia Type:

beta-

Thalassemia Severity:

Unknown

Population Found in:

Lebanese (Rare mutation)

Comments:

Mutation can also be referred to as IVS-I(-3)(C->T), Change in
amino acid code Gly->Glv. The substitution occurs 2 nucleotides
upstream of the GT splice donor site creating a new, competing.
splice donor site (Normal splicing - GGC AGjGTTGGT ->
Abnormal splicing - GiGTAGGTTGGT). As some normal splicing
of the mRNA still occurs the mutation results in beta4- thalassemia.

References:

• Chehab FF. Der Kaloustian V. Khouri FP, et al. The molecular
basis of beta-thalassernia in Lebanon: application to prenatal
diagnosis. Blood. Apr 1987; 69(4): 1141-5.

Record Added Last
Updated By:

Shaluon February 2], 200S at 11:00:50 am

Figure 3.5. The mutation details page.
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3.5 The New Mutation Input Form
Design of the New Mutation Input Form. The mutation input form allows the curator of
the database to add new mutation records to the database. The input form can be seen in
Figure 3.6.
Mutation ID: 107
Mutation Description: [Example: -56(G->C;
Mutation Type:

~3

-Choose one-|Enter new Mutation Type here

Starting Position:

Eg -56

Mutation Length:

Eg:1

Mutation Location:

Example: Promoter

-3

Mutation Effect:
Enter new Mutation Effect here,

Disease Type:

Disease Severity:

C beta* (silent)
(f beta*
<~ betaO
<~ beta(0 or + unclear)
r Thalassemia Major
f Thalassemia Intermedia
F" Thalassemia Minor
P Unknown

"3

Comments:

Distribution:

A*f'W )

Delete row |

References:

Add row |

Delete row

Insert record j

Reset form

Figure 3.6. The new mutation input form.
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The Mutation ID is automatically generated. An example is provided on how to
enter the Mutation Description. An existing Mutation Type can either be chosen from a
drop-down box or a new Mutation Type can be entered into a text box. If a Mutation
Type is selected from the drop-down box, the text box is disabled, and vice-versa, to
ensure that just one Mutation Type is entered for a mutation. The selection list of the
drop-down box is drawn from the existing values in the database. The Starting Position of
the mutation refers to the map position of the first base that is mutated. In case of an
insertion, the base position of the first base in the insertion is taken as the Starting
Position. For instance, if a base C is inserted between an A (position +40) and a T
(position +41), the inserted base C is now at position +41 and hence +41 is taken as the
Starting Position of the insertion.
The Mutation Length specifies the number of bases involved in the mutation.
Examples for the Starting Position and Mutation Length are included in their respective
text boxes. Clicking inside the text box removes the example, thus emptying the text box
for data entry. An example is provided, in a similar manner, for Mutation Location.
Mutation Effect is dealt with much like Mutation Type where both a drop-down box, for
existing values, and a text box for the entry of new values is provided. Just one Mutation
Effect, an existing one or a new one, can be added. Radio buttons are provided for
Disease Type where only one selection can be made. On the other hand checkboxes are
provided for Disease Severity where multiple choices can be made. The same mutation
can result in different disease severities depending on whether the individual has just one
mutated allele, has two mutated alleles, or has other modifying factors present. If the
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Unknown option is selected for Disease Severity the other options are disabled and viceversa.
The Comments text area has a character counter on the side which can be seen in
Figure 3.7. If the character count exceeds the limit, an error message is displayed.
Dreamweaver's Spry framework was used to add the character counter.

Comments: WoraRKAwas found.

18

Figure 3.7. The Comments text area with a character counter (seen on the
bottom right).
The Distribution includes the Nationality, Ethnicity, and Frequency.

The

Nationality can be selected from a drop-down box of existing nationalities or a new
nationality can be entered into the provided text box. The Ethnicity can be typed into a
text box. The Frequency can be selected from one of 4 fixed values - Common, Rare,
Novel, and Unknown. As a single mutation can be found in multiple populations, an Add
Row button is provided to enable the addition of multiple distributions. The Delete Row
button can be used to delete an unwanted row or record.
The References were handled in a similar manner where Add Row and Delete
Row buttons were provided to enable the addition of multiple records. Each reference
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has a Reference ID that is automatically generated. Text boxes are provided for the
PubMed ID (PMID), the names of the first three authors, the title of the article, the
volume number, the issue number, the year of publication, and the page numbers. Dropdown boxes are provided for the name of the journal and the month of publication.
While the Month drop-down box contains a fixed set of values, the Journal drop-down
box contains a selection list based on the existing journal names in the database. A
check-box is provided to indicate whether the article has more than 3 authors. The page
numbers can be entered by the curator as abbreviated numbers (301-10) or as complete
numbers (301-310). If the pages are entered as complete numbers, the underlying code
converts the numbers to the abbreviated format that is used in reference citations.
Finally, two buttons are available at the bottom of the page, the Insert Record
button allows the entered values to be submitted to the database, while the Clear Form
button resets all the fields enabling values to be re-entered.
The contents of a field are checked dynamically and errors messages are
generated, without refreshing the page, using Dreamweaver's Spry framework. Sample
error messages can be seen in Figure 3.8.
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Starting Position: f£66'
Mutation Length: JEgii

The map begins at -120.
A value is required.

Figure 3.8. Dynamically generated error messages. The first message
prompts the user to enter a valid value for the starting position while the second
message warns the user about a blank field.

Underlying Code for the New Mutation Input Form. HTML form elements were used
to create the page. In addition, a combination of PHP, JavaScript, and Dreamweaver's
Spry framework was used to make the page dynamic. PHP was used to populate the
drop-down boxes with existing database values and to insert the entered values into the
appropriate tables and columns. The curator name and the date and time of record entry
are automatically added to the database using PHP. PHP was also used to abbreviate the
page numbers prior to entry into the database. On the other hand, JavaScript was used to
disable or enable form elements, based on changes made by the user. JavaScript was also
used to reset the form, and to add and delete rows to tables. Dreamweaver was used for
form validation and for generating error messages.

3.6 The Mutation List
Design of the Mutation List Query Page. The query page allows database users to
generate mutation lists. The users can either choose to look at a list of all the mutations
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in the database or they can create a mutation list that is filtered based on various user
defined criteria. The query page can be seen in Figure 3.9.

Mutation List - Query Page
<~ Show imfiltered mutation list

<~ Show filtered mutation list
Filter by Nationality-: |-Choose one-

3

Filter by Mutation Frequency: J—Choose one—_J
Filter by Ethnicity: | —Choose one— 2I
Filter by Disease Type: |—Choose one—
Filter by Disease Severity: j -Choose one-

J
3

Submit

Figure 3.9. The mutation list query page. This page allows web site users to
create filtered or unfiltered mutation lists.
The web site user can filter the mutations based on Nationality. The drop-down
box provides a list of the nationalities currently available in the database. The user can
also filter the mutation list by disease severity, disease type, and mutation frequency.
Some of the ethnicities that frequently occur in the database are provided in the Ethnicity
drop-down box. The list of ethnicities is a static list and can be seen in Figure 3.10.
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Filter by Ethnicity: [ —Choose one— Irl
Filter by Disease T>| Black
Filter by Disease Se

Submit I

Chinese
Greek
Italian
Jew
Maharashtrian
Muslim
Punjabi
Southern Chinese
Southern Italian

H

U

Figure 3.10. Options available for filtering mutations by ethnicity.

Underlying Code for the Mutation List Query Page. HTML form elements were used to
create the page. PHP was used to generate the dynamic list for the Filter by Nationality
drop-down box.
Design of the Mutation List Page. The list page displays a filtered or unfiltered list of
records from the database. The list page can be seen in Figure 3.11. The number of
mutations and associated references found is displayed above each table. The only fields
excluded from the mutation list are Comments and Updation Date and Time.

The

reference titles, as in the mutation details page, link to the article abstract in PubMed.
The Reference ID, which was omitted from the details page, can be seen here.
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Mutation List
1 Riutation(s) fount I.
Mut. ,.
. .
Description
IT.,
ID

,,.
Jvpe

Startine
,,
„ . . *- Length Location
Position
Intron 1

81

IVS-L 3'
Deletion 256
end; -17bp

17

Position
+114 to
+130

_,.,- ,
tnect

Disease
,_
Ivpe

Disease
Seventy

r.

_. .,
Entered
Distnbution
Bv

mRNA
processing
Abolishes betaO
splicing at
3' splice
site

Unknown Kuwaiti

Shalu

Reference List
1 refexence(s) found.

106

3048433

Cazazian
HH Jr.
3oehm CD

Molecular basis and prenatal
diagnosis of beta-thalassemia.

Blood

7T

4

Oct 1988

110716

Figure 3.11. A sample mutation list. This list is generated when the option
Filter by Nationality: Kuwaiti is chosen.

Underlying Code for the Mutation List Page. When the user clicks on the Submit button
of the query page, the user's selections are passed, as variables, to the file containing the
code for generating the list page. PHP and HTML elements were used to generate the list
page. Based on the user's choice of filter, a query is constructed. PHP is then used to
connect to the database and obtain the relevant records from the database. HTML is used
to generate the table of records.

45

The following chapter provides some statistics based on records currently in the
database. It also enlists some conclusions that could be made by examining the database
contents.
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Chapter 4 The Database Content
As of now, the database contains 106 mutations. These mutations are located in
the promoter, the 5' and 3' UTRs, the open reading frame and the first intron. A listing
of all 106 mutations can be seen in Appendix B. Given below are some statistics based
on the records in the database:
Mutation Locations
•

Twenty-eight of the mutations are located in the promoter of the gene. Nearly
all of these mutations are found in the regulatory elements. Most of the
promoter mutations are found in the TATA box, followed by the proximal
CACCC box. Fewer mutations are based in the CCAAT box and the distal
CACCC box.

•

Eight of the mutations are located in the 5'UTR, while nine mutations fall in
the 3'UTR. Most of the 3'UTR mutations are located in the polyadenylation
signal sequence, AATAAA.

•

Most of the open reading frame mutations are found in Exon 1 (40 of a total of
55 exonic mutations).

•

Nine mutations are based in Intron 1. The majority of these mutations affect
the intronic 5' and 3' splice consensus sequences.

•

Most base positions have one or two mutations associated with them,
however, bases -87, +52, +53, and +144 have three attached mutations each.
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-87 is part of the proximal CACCC box, +52 and +53 are part of the start
codon (ATG), while +144 is part of the important GT dinucleotide of the
intron 1-5' splice consensus sequence.

Mutation Effects
•

The processes most often affected by the mutations are transcription followed
by mRNA translation.

Mutation Types
•

Substitutions are the most frequently seen type of mutations (68 of 106)
amongst which transversions are slightly more common than transitions.
Deletions (30) are seen far more often than insertions (8).

•

The longest mutation in the database is a 105 base pair deletion, extending
from base positions -25 to +80. However, overall, there are fewer insertions
or deletions involving more than two bases. Large deletions, that involve
more than the beta globin gene, have been excluded from the database.

Mutation References
•

Almost all the 106 mutations in the database, with the exception of 4, have
curator comments attached that are drawn from the references.

•

The mutations reference some 139 different sources.
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•

The largest number of references are drawn from the journal Hemoglobin
followed by the British Journal of Haematology.

•

The oldest article in the database is from June 1979, while the latest article
referenced is from February 2008.

•

Two of the mutations have six associated references. The article that is
referenced the most (six times) by various records is beta-thalassemia
mutations in Japanese and Koreans (Ohba, Hattori, Harano, Harano,
Fukumaki, & Ideguchi, 1997).

Disease Types
•

Most of the mutations result in a disease type of betaO (56 of 106).

Disease Distribution
•

The database includes 46 nationalities and 45 different ethnicities.

•

The nationality with the most associated mutations are Asian Indians (13
mutations), followed by Turks (12).

•

The ethnicities that have the most mutations in the database are US-Blacks
(10), followed by Asian Indian - Punjabis (4). Ashkenazi, Sephardic, and
Kurdish Jews (belonging to different countries like Iran, Israel, Russia, and
Canada) have 6 associated mutations in the database.
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•

Twelve of the mutations have a high frequency (are common mutations) in the
population in which they are found. The remaining are rare (28) or novel (46)
or have an unknown frequency (42).

Most of the above statistics are reflective of what one would expect to find with
beta thalassemia mutations. For instance, most beta thalassemia mutations are known to
be substitutions (Giardine et al, 2007), a few common mutations are found in each
population while the majority of mutations are rare or novel (Weatherall, 2004).
By studying and comparing the properties of the various mutations in the
database, some interesting conclusions can be drawn. Furthermore, information can be
obtained about the disease and its variations by looking at the given curator comments.
Some examples of what one could learn about thalassemia, by examining the database
contents, are given below:
Patient Genotype
•

Most severely affected

patients of beta thalassemia are compound

heterozygotes for two beta thalassemia alleles or a beta thalassemia allele and
a hemoglobin variant. Hemoglobin variants are beta globin mutations that
affect the quality of hemoglobin as opposed to the quantity.
•

Homozygous beta thalassemia results from consanguineous marriages, that is,
marriages between relatives such as first-cousins. This is seen amongst the
Jewish Kurds, who are a highly in-bred ethnic group.
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Beta Thalassemia in Different Populations
•

Black patients, from the US, tend to have a milder form of thalassemia. The
mutations they carry usually lead to beta+ thalassemia and thalassemia
intermedia. Black patients, also, often have a thalassemia mutation associated
with HbS, the sickle-cell anemia causing hemoglobin variant.

•

Patients from Northern Africa (Algeria and Tunisia) also show compound
heterozygosity with HbS.

•

Most Thai patients carry a thalassemia mutation combined with the
hemoglobin variant HbE.

•

The island of Corsica is the only place in France where beta thalassemia is
endemic.

•

A promoter mutation (-29 (A->G)) is the most common mutation found in
both US-Blacks and Chinese. However, the same mutation may have likely
arisen independently in the two populations as no major interactions, between
the two populations, have occurred.

•

Mutations found in New World patients (US, Canada, Mexico, Surinam) and
Northern European patients are seen as a result of immigration from regions
where thalassemia has been prevalent such as Africa, Southern Europe, the
Middle-east, and India. A few mutations in these regions are the result of
novel mutations.

•

Beta thalassemia is a severe disorder amongst Bulgarians and Sardinians. On
the island of Sardinia beta thalassemia arose as a single mutational event.
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Disease Type and Severity
•

Most of the promoter and UTR mutations tend to result in a milder disease, as
they cause only beta+ or silent beta+ thalassemia. Silent beta thalassemia is a
very mild form of beta thalassemia; patients heterozygous for such mutations
are hematologically normal and the condition is only detected when combined
with another more severe beta thalassemia mutation.

Promoter and UTR

mutations frequently result in thalassemia intermedia.
•

Exonic mutations usually affect the open reading frame and hence result in
betaO thalassemia and thalassemia major. The mRNA transcript carrying a
frame-shift mutation is generally destroyed prior to translation.

•

Intronic mutations result in betaO thalassemia and thalassemia major as they
tend to affect splicing. The improperly spliced mRNA transcripts are
destroyed prior to translation.

Mutation Locations
•

The majority of the disease-causing promoter mutations are located in the
regulatory elements of the promoter, as these regions are important for the
binding of transcription factors and the efficient initiation of transcription.
The distal CACCC box has fewer mutations than the proximal CACCC box,
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although the same factors bind to both, suggesting that the proximal box plays
a more important role in transcription initiation.
•

When a region or a base does not have mutations associated with it, it just
means that no patients have been found carrying a mutation at that position or
within that region, most likely because the mutation has little or no effect on
the individual. There is also a small likelihood that the region in question is
somewhat less prone to mutations, for instance, due to the presence of fewer
repeats. As such, overall, the beta globin gene is considered a hot-spot for
mutations (Das & Talukder, 2001).

Mutation Effects
•

Silent mutations, that do not change the amino acid encoded by a codon, may
not seem to affect the polypeptide sequence, but may actually cause disease
by disrupting a splice site.

•

Some seemingly harmless mutations in the exons or introns may give rise to
cryptic splice sites which may compete with the actual splice sites.

•

The destruction of a splice site due to a mutation may at times give rise to
multiple cryptic splice sites that are then utilized as alternatives.

•

Some mutations create or disrupt the recognition site for a restriction enzyme.
This fact may help in the identification of a mutation.
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Disease Variants
•

If a beta thalassemia mutation is simultaneously inherited with an alpha
thalassemia, the carrier of the mutations may have a milder disease or may be
totally asymptomatic.

The presence of both types of thalassemias helps

reduce the imbalance between the alpha and globin chains thus reducing
disease severity.
•

If a beta thalassemia mutation is simultaneously inherited with a mutation in
the gamma globin gene, a less severe form of beta thalassemia is seen. The
gamma globin gene encodes gamma globin, a component of the fetal
hemoglobin, HbF. Certain mutations in the gamma globin gene cause fetal
hemoglobin to persist into adulthood, a condition referred to as the Hereditary
Persistence of Fetal Hemoglobin (HPFH). Patients that simultaneously inherit
beta thalassemia and HPFH usually suffer from thalassemia intermedia
instead of major.

•

Promoter mutations in the beta globin gene sometimes lead to an indirect
increase in the production of delta globin, a component of the minor adult
hemoglobin HbA2.

As beta and delta globin have a close evolutionary

relationship, the similar promoter regulatory elements in the delta globin gene
may compete for the common transcription factors.

An increase in delta

globin production leads to a less severe disease and likely results in
thalassemia intermedia.
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•

The insertion of a codon may give rise to a dominant betaO thalassemia. The
abnormal mRNA is translated into a beta chain with an extra amino acid
which does not bind to the alpha-chain, resulting in dominant betaO
thalassemia. This condition results in the destruction of beta chains and an
accumulation of alpha chains.

Mutation Types
•

Beta thalassemia is mostly caused by substitutions.

Also, substitutions

involving transversions are more likely to cause disease than those involving
transitions. This can be explained by the fact that transversions involve a
dramatic change in chemical structure.
•

Most disease causing insertions and deletions are those that lead to
frameshifts.

This is expected as frameshifts would majorly alter the open

reading frame of the gene.
•

Most insertions and deletions are found in regions of short repeats. The
repeats could lead to slipped strand mispairing, during DNA replication,
which would in turn result in an insertion or deletion.

The following chapter puts forward some ideas for the further enhancement of the
created database.
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Chapter 5 Plans for Future Improvements
Given below are some of the suggestions for improvement of the Beta
Thalassemia Database:
•

Input Form
o Users can be provided with a guide on how to enter a mutation using
the form.
o The functionality of the form can be improved. For instance, along
with the delete row option the users can be allowed to choose the row
to be deleted (as of now only the last row can be deleted).
o More Ajax driven error checks can be added to the form.

•

Mutation List
o The user can be allowed to choose which columns are to be included
in the mutation list,
o A filter allowing display of mutations by continent or world region
could be added,
o More complex compound queries, combining two or more filters can
be added. For example, users could be allowed to filter mutations by
nationality and disease severity.

•

Overall Improvements
o More mutations could be added.

56

o Users could be allowed to login, leave comments for a mutation or
leave suggestions. A user forum could also be provided,
o Thalassemia information and resources for patients could be included,
o

Links to the latest thalassemia news could be provided,

o

Information could be provided to students about
•

the functions of various parts of a gene,

•

mutation nomenclature,

•

the causes of different types of mutations,

•

the effects of different mutations,

•

the inheritance of thalassemia,

•

the relation between malaria and thalassemia,

•

thalassemia treatment and prevention,

•

the spread of thalassemia mutations within populations,

•

haplotypes and their use in the study of thalassemia mutations,

•

restriction enzymes and their use in detecting mutations,

•

information about beta thalassemia variants (e.g., thalassemia
intermedia,

silent

beta+

thalassemia,

dominant

betaO

thalassemia),
•

the structure of hemoglobin,

•

processes involved in the formation of hemoglobin from the

gene,
•

the different types of globins, and
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•

the evolution of the globins.

o Disease related information specific to a nationality or ethnicity could
be given.

Measures adopted by certain countries, like Cyprus, to

successfully reduce beta thalassemia rates could also be included.
o Authentication for the curator should be provided.
These improvements, if implemented, will make the web site easier to use as well
as more comprehensive and informative.
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Appendix A
Code for Automated Underlining of Hyperlinks
The following code detects which map positions in the mutation map have
associated mutations in the database and then proceeds to underline those map positions.
Underlining indicates that the map position is a hyperlink that can be clicked on to
display the details of the associated mutations.

This piece of code overcomes the

problem of having to manually convert map positions into hyperlinks every time the
database is updated and mutations are added to new positions.
<?php
require_once('Connections/conn2ThalassemiaDB.php');
//Declaring a PHP array.
$Und_pos_arr= array();
//For each map position, connecting to the database and determining if there are mutation
records associated with the position.
for ($Map_pos=-120; $Mapjpos <=+1706; $Map_pos++)
{
mysql_select_db($database_conn2ThalassemiaDB, $conn2ThalassemiaDB);
$query_Recordsetl = sprintf ("SELECT MUTATION.MutID FROM MUTATION
WHERE Strt_pos = %s", $Map_pos);
$Recordsetl =mysql_query($query_Recordsetl, $conn2ThalassemiaDB) or
die(mysql_error());
$row_Recordsetl = mysql_fetch_assoc($Recordsetl);
$num_rows=mysql_num_rows($Recordsetl);
//If mutations are found associated with a position, the map position is assigned to the
declared PHP array.
//If no associated mutations are found, when a user clicks on the map position, a popup
box is displayed.
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if ($num_rows > 0)
{
$Und_pos_arr[]=$Map_pos;
}
else
{?>
<script type="text/javascript">
<!--

var Norecs = document.getElementById(<?php echo $Mapjpos ?>);
No_recs.onclick= function showBox()
{
alert ("Sorry, no mutations recorded for this position.");
return false;
}
-->

</script>
<?php
}
}
?>

<!~When the page reloads, each map position stored in the PHP array is underlined~>
<script type="text/javascript">
<!--

window.onload= function Changes()
{
<?php foreach ($Und_pos_arr as $Und_pos)
{?>
document.getElementById(<?php echo $Undjpos ?>).style.textDecoration="underline";
<?php
}?>
}
—>

</script>
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<3\

-92(C->T)

-90(C->T)

-88(C->T)

3

4

-101(C->T)

2

1

1

1

1

Substitution -90
Transition

Substitution -88
Transition

1

Substitution -92
Transition

Substitution -101
Transition
Transcription

Transcription

Transcription

Transcription

Promoter
regulatory
element,
distal
CACCC
Promoter
regulatory
element,
proximal
CACCC
Promoter
regulatory
element,
proximal
CACCC
Promoter
regulatory
element,
proximal
CACCC

Given below is the the list of 106 mutations currently in the
database:

beta+

beta+

beta+
(silent)

beta+
(silent)

Intermedia

Unknown

Intermedia

Intermedia

US - Black (Common mutation) ,
Asian Indian Punjabi (Rare mutation)

Portuguese (Rare mutation)

Sicilian (Rare mutation)

Turkish (Rare mutation),
Bulgarian (Rare mutation),
Italian - Southern
Italian (Rare mutation)

List of Mutations in the Beta Thalassemia Database

Appendix B

-88(C->A)

-87(C->G)

-87(C->T)

-87(C->A)

-86(C->G)

-86(C->A)

-32(C->A)

5

6

7

8

9

10

11

1

1

1

1

1

1

1

Substitution -88
Transversion

Substitution -87
Transversion

Substitution -87
Transition

Substitution -87
Transversion

Substitution -86
Transversion

Substitution -86
Transversion

Substitution -32
Transversion

beta+

beta+

Transcription

Transcription

Transcription

Transcription

Promoter
regulatory
element,
proximal
CACCC
Promoter
regulatory
element
proximal
CACCC
Promoter
regulatory
element
proximal
CACCC
Promoter
regulatory
element
proximal
CACCC

Promoter
regulatory
Transcription
element
TATAboxCATAAAA

beta+

beta+

beta+

beta+

Transcription

Promoter
regulatory
element,
proximal
CACCC

beta+

Transcription

Promoter
regulatory
element
proximal
CACCC

Minor

Intermedia

Major

Intermedia

Intermedia

Intermedia

Intermedia

mutation).

Taiwanese - Fukien
Taiwanese (Novel mutation)

Italian (Rare mutation)

Thai (Rare
Lebanese

US - Black (Novel mutation)

German,
Italian - GermanItalian (Rare mutation)

Sardinian (Rare mutation),
Turkish (Rare mutation),
Italian (Rare mutation)

Iranian - Kurdish Jew

-31(A->G)

-31(A->C)

-30(T->A)

-30(T->C)

-29(A->G)

-28(A->C)

-28(A->G)

12

13

14

15

16

17

18

1

1

1

1

1

1

1

Substitution -31
Transition

Substitution -31
Transversion

Substitution -30
Transversion

Substitution -30
Transition

Substitution -29
Transition

Substitution -28
Transversion

Substitution -28
Transition

beta+

beta(0
or +
Unknown
unclear)

beta+

beta+

beta+

Promoter
regulatory
element.
Transcription
TATA boxCATAAAA
Promoter
regulatory
element
Transcription
TATA boxCATAAAA
Promoter
regulatory
element
Transcription
TATA boxCATAAAA
Promoter
regulatory
element
Transcription
TATA boxCATAAAA
Promoter
regulatory
element.
Transcription
TATA boxCATAAAA

Intermedia

Major

Minor

Intermedia

Unknown

beta+

Promoter
regulatory
element
Transcription
TATA boxCATAAAA

Intermedia

beta+

Promoter
regulatory
element,
Transcription
TATA boxCATAAAA

Chinese (Common mutation)

Israeli - Kurdish Jew

US - Black (Common mutation) ,
Chinese (Common mutation)

Chinese - South-eastern Chinese
(Fujian province) (Novel mutation)

Macedonian (Rare mutation) ,
Turkish (Rare mutation) ,
Tunisian (Rare mutation)

Italian (Novel mutation)

Japanese (Common mutation)

1

1

1

1

2

1

Substitution -25
Transversion

Substitution -93
Transversion

Substitution -56
Transversion

Substitution -32
Transition

-27

Substitution -102
Transversion

-25(G->C)

-93(C-XJ)

-56{G->C)

-32(C->T)

-27(-AA)

-102(C->A)

20

21

22

23

24

25

Deletion

1

Substitution -27
Transversion

-27(A->T)

19

Intermedia

beta+
(silent)

Promoter
regulatory
element,
distal
CACCC

Transcription

beta(0
or +
Intermedia
unclear)

Promoter
regulatory
element,
Transcription
TATA boxCATAAAA

Unknown

beta(0
or +
Unknown
unclear)

beta+

Transcription

Promoter
regulatory
element.
Transcription
TATA boxCATAAAA

Promoter

Unknown

beta+

Promoter
regulatory
element,
proximal
CACCC
Transcription

beta(0
Unknown
or +
unclear}

Promoter
regulatory
element,
Transcription
TATAboxCATAAAA

Minor

beta+

Promoter
regulatory
element.
Transcription
TATAboxCATAAAA

French - Tunisian(North
African) (Novel mutation)

US - Black (Novel mutation)

Canadian Hispanic (Novel mutation)

Morrocan

Surinamese

US - Black

French - Corsican (Novel mutation)

1

1480

Substitution Transversion

+1480(C->G)

36

4

40

Deletion

CAP +40{-AAAC)

35

1

Substitution 33
Transversion

CAP +33(C->G)

34

1

Substitution 22
Transition

CAP +22(G->A)

33

1

Substitution 20
Transition

CAP +20(C->T)

32

1

Deletion

CAP +10(-T)

31

10

1

Substitution 8
Transition

CAP +8(C->T)

30

1

1

Substitution Transversion

CAP +1(A->C)

29

105

-25

Deletion

105 bp del (-25 to 80)

28

1

Substitution -101
Transversion

-101(C->G)

27

1

Substitution -73
Transversion

-73(A->T)

26

3'UTR

5'UTR

5'UTR

5'UTR

5'UTR

5'UTR

Intermedia

Unknown

Transcription,
beta+
mRNA stability
beta+
(sflent)

Intermedia

Intermedia

Transcription,
mRNA stabflity | " ^
Transcription,
beta+
mRNA stability (silent)

Intermedia

Intermedia

Transcription, 1 beta+
mRNA stability (silent)
Transcription. L
mRNA stability | ****

Unknown

mRNA stability

Thai

Russian - Ashkenazi Jew

Chinese - Southern
Chinese (Novel mutation)

Greek (Rare mutation)

Chinese (Novel mutation)

Cypriot - Greek

Canadian - Italian (Novel mutation)

Turkish,
Bulgarian

Greek (Novel mutation)

Chinese (Novel mutation)

Intermedia,
Asian Indian Major,
Punjabi (Rare mutation)
Minor

Unknown

Intermedia

Intermedia

beta+
| , M .,.
j (silent)

T
. ,.
Transcription
r

beta+
L, ~ .

5'UTR (1st
„
. ,.
base to be Transcnpbon
transcribed)
5'UTR

| betaO

Transcription

beta+

I , •• >

Promoter5'UTRExonl(Cd
9)

• ,-

beta+
L ^

Transcription

_

- ..
Transcription
T

Promoter
regulatory
element,
distal
CACCC

Promoter
regulatory
element,
CCAAT
box

1

1

1

1585

Substitution Transition

Substitution 1586
Transition

Substitution 1587
Transition

Deletion

Deletion

+1521(C->G)

+1585(A->G)

+1586(A->G)

+1587(A->G)

+1582(-AATAA)

+1584(-TA)

40

41

42

43

44

45

1584

2

5

1

Substitution 1521
Transversion

+1584(T->C)

39

1582

1

1584

Substitution Transition

1

1570

13

Substitution Transition

1565

+1570(T->C)

+1565(Deletion
GCATCTGGATTCT)

38

37

mRNA
cleavage and
beta+
polyadenylation

3'UTR.
PolyA
signal
AATAAA
Unknown
mRNA
cleavage and
beta+
polyadenylation
mRNA
cleavage and
beta+
polyadenylation
mRNA
cleavage and
beta+
polyadenylation
mRNA
cleavage and
beta+
polyadenylation
mRNA
cleavage and
beta+
polyadenylation

3'UTR
3*UTR,
PolyA
signal
AATAAA
3'UTR.
PolyA
signal
AATAAA
3'UTR,
PolyA
signal
AATAAA
3'UTR,
PolyA
signal
AATAAA
3'UTR.
PolyA
signal
AATAAA

beta+

mRNA stability beta+

Canadian - Irish (Novel mutation)

Turkish (Navel mutation)

Malay (Rare mutation)

Macedonian (Rare mutation),
Bulgarian (Rare mutation),
Greek (Rare mutation)

Armenian

I Unknown

Major

US - Black,
French Normandy (Novel mutation)

UAE,
Israeli - Arab Muslim
(Gaza) (Novel mutation)

Intermedia, Israeli - Kurdish
Major
Jew (Common mutation)

Unknown

Unknown

Unknown

Intermedia, Turkish (Rare mutation),
Major
US - Black (Rare mutation)

Minor

beta(0
Unknown
mRNA stability or +
unclear)

3'UTR

3'UTR

1
1

1

1

Substitution 52
Transition
Substitution 52
Transversion
Substitution 53
Transversion
Substitution Transition,
53
Missense
Substitution Transversion, 53
Missense
54

57

Deletion Frameshift
Deletion &
Insertion Frameshift
Substitution Transversion
(Codon 4,6),
Transition
(Codon 5),
65
Silent(Codon
4), Missense
(Codon 5),
Nonsense
(Codon 6)

Start codon(ATG>ACG)

Start codon(ATG>AGG)

Start codon(ATG>ATC)

Start codon(ATG>ATA)

Start codon(ATG>ATT)

Codon 1(-G). (GTG>TG)

Codons 2/3/4{-9bp:
+31bp)

Codon 4{ACT>ACA). Codon 5
(CCT->TCT), Codon
6(GAG->TAG)

47

48

49

50

51

52

53

54

55
5

9

1

1

1

Substitution 52
Transversion

Start codon(ATG>AAG)

1

Substitution 51
Transition

Start codon(ATG>GTG)

46

Exon 1 Codons
4,5,6

Exon 1 Codons
2,3,4

Exon 1 Codon 1

mRNA
translation

mRNA
translation

mRNA
translation

Exon 1 mRNA
Start codon translation

Exon 1 mRNA
Start codon translation

betaO

betaO

betaO

betaO

betaO

betaO

betaO

mRNA
Exon 1,
Start codon translation
Exon 1,
mRNA
Start codon translation

betaO

Exon 1,
mRNA
Start codon translation

Major,
Minor

Unknown

Unknown

Unknown

Minor

Unknown

Unknown

Unknown

Asian Indian - North Indian
(Lucknow)

Algerian (Novel mutation)

Sardinian (Novel mutation)

Iranian

Italian,
Swedish - Northern Swedish

Japanese (Novel mutation)

Chinese (Novel mutation),
Korean (Common mutation)

Croatian (Rare mutation) ,
Swiss - Bern (Novel mutation) ,
Belgian

Canadian - North
beta(0
Intermedia, European (Novel mutation),
or +
Minor
French - Caucasian(South-eastem
unclear)
French)

Japanese (Rare mutation)

mRNA
Exon 1,
Start codon translation

Unknown

betaO

mRNA
Exon 1,
Start codon translation

1

2

1

1

Substitution Codon 7(GAG->TAG) Transversion, 72
Nonsense
75

78

81

Codon 8(-AA), (AAG- Deletion >G)
Frameshift

Codon &/9(+G), (AAG Insertion T C T - > A A G G T C T ) Frameshift

Codons 9/10(+T),
Insertion (TCT GCC -> TCT T
Frameshift
GCC)
Substitution Transversion, 83
Silent

58

59

60

61

1

1

1

96

Codon 11(-T).(GTT- Deletion Frameshift
>GT)
Insertion Frameshift
Substitution - J
Transition,
197
Nonsense
j
Substitution Transition,
98
Nonsense

Codons 14/15(+G).
(CTG TGG -> CTG
GTGG)

Codon 15(TGG>TAG)

Codon 15(TGG>TGA)

63

64

65

66

1

86

Codon 10(GCC>GCA)

62

1

1

70

Deletion Frameshift

Codon 6(-A). (GAG>GG)

57

2

67

Codon 5(-CT). (CCT- Deletion Frameshift
>C)

56

beta+

mRNA
processing Creates cryptic
splice site in
exon

Exon 1 Codon 15

mRNA
| translation

mRNA
translation

mRNA
translation

Exon 1 Codons
14/15
Exon 1 Codons 15

mRNA
translation

Exon 1 Codon 11

betaO

betaO

betaO

betaO

betaO

mRNA
translation

Exon 1 Codons
9/10

Exon 1 Codon 10

betaO

Exon 1 mRNA
Codons 8/9 translation

betaO

betaO

betaO

betaO

mRNA
translation

mRNA
translation

mRNA
translation

mRNA
translation

Exon 1 Codon8

Exon 1 Codon 7

Exon 1 Codon 6

Exon 1 Codon 6

Major,
Minor

Intermedia

Major

Unknown

Major

Unknown

Intermedia

Unknown

Unknown

Major

Major

Japanese,
Portuguese - Central
Portuguese (Common mutation)

Asian Indian (Common mutation) .
Turkish (Rare mutation) ,
Japanese

Chinese - Southern Chinese
(Guangdong
province) (Novel mutation)

Mexican - Mestizo (Novel mutation)

Asian Indian - Central Indian
(Madhya Pradesh) (Novel mutation)

Greek (Novel mutation)

Japanese,
Asian Indian

Turkish - South-eastern Turkish
(Gaziantep),
Israeli

British - English

Bulgarian,
US - Black(South-eastern US),
US - Southern Italian,
Italian - Southern Italian
(Calabria) (Rare mutation)

Greek (Rare mutation)

Deletion Frameshift

1

1

1

Substitution Transversion, 117
Nonsense
118

123

129

130

135

Insertion Frameshift
Insertion Frameshift

Codons 22/23/24(-7
bp), (-AAGTTGG)

Deletion &
Codon 24(-G; +CAC),
Insertion(GGT -> CAC GT)
Frameshift

Substitution Transversion. 129
Nonsense
135

Deletion Frameshift

Codon 22(GAA>TAA)

Codons 25/26(+T).
(GGT GAG -> GGT
T GAG)

Codon 26(+T). (GAG
-> GTA G)

Codon 26(GAG>TAG)

Codons 27/28(+C).
Insertion (GCC CTG -> GCC C
Frameshift
CTG)

Codon 28(-C). (CTG- Deletion Frameshift
>TG)

71

72

73

74

75

76

77

78

1

1

1

1

7

1

Substitution Transversion, 102
Nonsense

1

1

1

101

99

96

Codon 17, (AAG>TAG)

Codon 16(-C), (GGC- Deletion >GG)
Frameshift

QC)

Codons 15/16(-G),
(TGG GGC -> TGG

Codon 15(-T). (TGG- Deletion >GG)
Frameshift

70

69

68

67

Exon 1 Codon 28

Exon 1 Codons
27/28

Exon 1 Codon 26

Exon 1 Codon 26

Exon 1 Codons
25/26

mRNA
translation

mRNA
translation

mRNA
translation

mRNA
translation

mRNA
translation

mRNA
translation

mRNA
translation

Exon 1 Codons
22/23/24
Exon 1 Codon 24

mRNA
translation

mRNA
translation

mRNA
translation

mRNA
translation

mRNA
translation

Exon 1 Codon 22

Exon 1 Codon 17

Exon 1 Codon 16

Exon 1 Codons
15/16

Exon 1 Codon 15
Major

betaO

betaO

betaO

betaO

betaO

betaO

betaO

betaO

betaO

betaO

Unknown

Major

Major

Unknown

Major

Major

Major

Unknown

Unknown

Unknown

beta(0
or +
Minor
unclear)

betaO

Egyptian (Novel mutation)

Chinese (Novel mutation).
Taiwanese - Hakka
Taiwanese (Novel mutation)

Thai - North-eastern
Thai (Novel mutation)

Japanese (Novel mutation)

Tunisian (Novel mutation)

Egyptian (Novel mutation)

Turkish (Novel mutation)

Reunion Island (Novel mutation)

Chinese

Asian Indian (Rare mutation)

German (Novel mutation)

Malay (Novel mutation)

Codon 39(CAG>TAG)

Codon 40(-G). (AGG- Deletion Frameshift
>AG)

84

85

Codon 30(AGG>GGG)

Substitution Transition,
298
Nonsense

Codons 38/39(-CC),
(ACC CAG -> A
CAG)

83

86

296

Deletion Frameshift

Codon 24(GGT>GGA)

82

Substitution Transition,
Mis sense

1

Substitution Transversion, 125
Silent

IVS-L 3' end: -17bp

81

141

302

2

256

Deletion

Codon 29(GGC>GGT)

80

1

1

1

17

1

140

Substitution Transition,
Silent

1

137

Deletion Frameshift

Codons 28/29(-G).
(CTG GGC -> CT
GGC or CTG GC)

19

beta+

mRNA
processing Creates cryptic
splice site in
exon

Intron 1 Position
+114 to
+130

Exon 1 Codon 30

Exon 2 Codon 40

Exon 2 Codon 39

Exon 2 Codons
38/39

betaO

betaO

mRNA
processing Abolishes
splicing at 5'
splice site

betaO

mRNA
translation

mRNA
translation

betaO

betaO

mRNA
processing Abolishes
splicing at 3'
splice site

Exon 1 Codon 29

mRNA
translation

beta+

mRNA
processing Creates cryptic
splice site in
exon

Exon 1 Codon 24

betaO

mRNA
translation

Exon 1 Codon 29

Kuwaiti

Lebanese {Rare mutation)

Japanese {Rare mutation),
Egyptian {Rare mutation)

Belgian (Novel mutation)

Unknown

Unknown

Canadian - Sephardic
Jew (Novel mutation)

Japanese

Sardinian {Common mutation) ,
Intermedia,
Italian (Common mutation),
Major
Turkish

Unknown

US - Black(South-eastern
Intermedia,
US) {Rare mutation) ,
Minor
Japanese

Unknown

Unknown

Unknown

Deletion Frameshift

Codon 30{AGG>AGC)

Codon 31(-C). (CTG>TG)

Codons 30/31(+CGG) Insertion

89

90

91

Deletion Frameshift

Codons 36/37(-T).
(CCT TGG -> CCT
GG)

95

1

1

Substitution Transversion. 288
Nonsense

Codon 35(TAC>TAA)

94

291

1

288

Deletion Frameshift

Codon 35(-C). (TAC>TA)

44

93

126

Deletion Frameshift

44 bp deletion

3

92

274

1

1

Substitution Transversion, 273
Missense

Codon 40(+86 bp)

88

274

86

303

Insertion Frameshift

Codon 30(AGG>AAG)

87

1

142

Substitution Transition,
Missense

Exon 2 Codons
36/37

Exon 2 Codon 35

mRNA
translation

betaO

betaO

betaO

mRNA
translation
mRNA
translation

betaO

mRNA
processing Abolishes
splicing at 5'
splice site

Exon 1 Codon 25
to Intron 1
- Position
+27
Exon 2 Codon 35

betaO

Assembly of
hemoglobin
molecule

Exon 2 Codons
31/32

betaO

mRNA
processing AboKshes
splicing at 3'
spEce site
betaO

betaO

mRNA
translation

mRNA
translation

betaO

Exon 2 Codon 31

Exon 2 Codon 30

Exon 2 Codon 40

Exon 1 Codon 30

mRNA
processing Abolishes
splicing at 5'
splice site

Major

Major

Unknown

Major

Minor

Unknown

Unknown

Minor

Unknown

Iranian - Kurdish Jew(Western Iran),
Iranian - Muslim

Thai - core-Thai (Rare mutation)

Malay - Western
Malay (Rare mutation)

Macedonian,
Greek

Spanish (Novel mutation)

Taiwanese Chinese (Novel mutation)

UAE

Portuguese - Northern
Portuguese (Novel mutation)

Bulgarian,
UAE

1

Substitution Transition,
293
Nonsense
294

296

Codons 37/38/39(-7
Deletion bp), (TGG ACC CAG
Frameshift
->TG)
Deletion Frameshift

Substitution 143
Transition

Substitution 143
Transversion

Substitution 144
Transversion

Codon 37(TGG>TAG)

Codons 38/39(-C).
(ACC CAG -> ACC
AG)

TVS I-1(G->A).
(AGIGTTGGT ->
AG|ATTGGT)

IVS I-1(G->T).
(AGIGTTGGT ->
AGITTTGGT)

TV'S I-2(T->G).
(AGIGTTGGT ->
AG|GGTGGT)

98

99

100

101

102

103

1

1

1

1

7

25

252

Deletion Frameshift

25 bp deletion

97

1

96

Substitution Transition.
294
Nonsense

Codon 37(TGG>TGA)

betaO

betaO

mRNA
processing Intron 1 AboKshes
Position +1
splicing at 5'
spHce site
mRNA
processing Intron 1 AboKshes
Position +2
splicing at 5'
splice site

betaO

betaO

betaO

mRNA
translation

mRNA
translation

betaO

betaO

betaO

mRNA
processing Intron 1 Abolishes
Position +1
splicing at 5'
spKce site

Exon 2 Codons
38/39

Exon 2 Codons
37/38/39

mRNA
translation

mRNA
processing Abolishes
splicing at 3"
splice site

Intron 1 Position
+110 to
Exon 2 Codon 31
Exon 2 Codon 37

mRNA
translation

Exon 2 Codon 37

Asian Indian

Unknown

Unknown

Major

Minor

Major

Tunisian

Asian Indian - Maharashtrian.
Asian Indian - Punjabi

Cypriot - Greek (Rare mutation) ,
Spanish - South-western Spanish
(Huelva province)
(Common mutation) ,
Turkish,
Czech

Czech (Novel mutation)

Turkish (Novel mutation)

Intermedia.
Afghan (Novel mutation)
Major

Unknown

Major

Spanish - Catalonian(Ebro
Delta) (Common mutation),
Saudi Arabian.
Jordanian

Substitution Transversion

Substitution Transversion

IVS I-2(T->A),
(AG|GTTGGT ->
AGIGATGGT)

IVS I-5(G->C).
(AG|GTTGGT->
AG|GTTGCT)

104

105

106

147

144

Substitution 144
Transition

IVS I-2(T->C).
(AG]GTTGGT->
AG|GCTGGT)

1

1

1

betaO

mRNA
processing Intron 1 Abolishes
Position +2
splicing at 5'
splice site

mRNA
Intron 1 processing beta+
Position +5 reduces splicing
at 5' splice site

betaO

mRNA
processing Intron 1 Abolishes
Position +2
splicing at 5'
splice site
US - Black,
Algerian (Rare mutation)

Asian Indian Punjabi (Common mutation),
Asian Indian Maharashtrian (Common mutation) .
Asian Indian - Oriya,
Chinese - Southern Chinese
Intermedia,
(Guangdong
Major
province) (Rare mutation),
Vanuatuan - Maewo
island (Common mutation) ,
German,
Papua New Guinean Coastal (Common mutation)

Italian - Southern
Intermedia.
Italian (Navel mutation),
Major
Algerian

Major

